Biotechnology

CSTONE PHARMA-B

CStone Pharmaceuticals Launches Share Repurchase Program Up to 136 Million Shares

CStone Pharmaceuticals Launches National Supply of Praseltinib Capsules in China

CStone Pharmaceuticals Initiates Commercial Launch of Locally Manufactured Pralsetinib Capsules

CStone Pharmaceuticals Releases 2025 ESG Report

Chi-Med Releases 2025 Annual Report Highlighting Pipeline 2.0 Progress

Chi-Med submits new share issuance involving 118 million shares

CStone Pharmaceuticals Announces Clinical Progress of PD-1/VEGF/CTLA-4 Tri-Specific Antibody CS2009

HHLR Advisors Increases Holdings in Chi Ma Pharmaceutical

CStone Pharmaceuticals Plans to Submit IND for CS5007 and Initiate Phase I Trial

CStone Pharmaceuticals Plans to Raise Funds for Oncology Drug Development

Chi-Med Starts Private Placement to Raise HK$1.1B for R&D

CMBI Raises Target Price for Chi-Med

CStone Pharma Reports Expanding Losses but Sees Stock Surge with New Drug Clinical Data

Goldman Sachs Maintains Buy Rating on Chi-Med and Sets Price Target

International investment institutions give positive evaluations on CStone's core product CS2009

CSTONE PHARMA-B released FY2025 Q3 earnings on March 26, 2026 (BJT) with actual revenue of HKD 120.32 M and EPS of HKD -0.0623

CSTONE PHARMA-B released FY2025 9 Months Earnings on March 26 (BJT), actual revenue HKD 173.86 M, actual EPS HKD -0.2897

CStone Pharmaceuticals Announces 2025 Annual Performance and Emphasizes Innovation and Sustainable Growth

CStone Pharmaceuticals Inc 2025 Revenue Down and Loss Expanded

CSTONE PHARMA-B released FY2025 annual earnings on March 26 After-Market (BJT), actual revenue HKD 294.64 M (forecast HKD 229.44 M), actual EPS HKD -0.344 (forecast HKD -0.2335)

CH DEMETER FIN

FAMEGLOW

LUEN THAI

NEW GONOW RV

REF HOLDINGS

PARADISE ENT

WEBX HOLDING

HAICHANG HLDG

BEST FOOD HLDG

INTELLIMARK W27

02616

CStone Pharmaceuticals (HK:2616) has announced a share buyback plan to repurchase up to 136,450,133 shares, following the upcoming American Society of Clinical Oncology meeting where new data on its trispecific antibody CS2009 will be presented. This initiative reflects management's confidence in the company's research and long-term strategy, aiming to enhance shareholder returns. The buyback's execution will depend on market conditions and board discretion. CStone, focused on oncology and immunology, has launched four innovative drugs and has a diverse pipeline of 16 candidates.

Tip Ranks

CStone Pharmaceuticals Unveils Share Buyback Plan After Key Oncology Data Milestone

510660

516500

520690

159615

513700

159506

159992

159102

CStone Pharmaceuticals has launched nationwide supply of its domestically produced pralsetinib capsules in China, enhancing local supply chain for this cancer therapy. The drug's sales surged over 430% year-on-year, with expectations to exceed RMB 300 million in 2026. This move aims to meet rising clinical demand and improve cost efficiency. Pralsetinib is approved for RET fusion-positive non-small cell lung cancer and thyroid cancer, reinforcing CStone's position in precision oncology in the region.

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Southern Hang Seng Biotech ETF(QDII)

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

ICBCCS SSE STAR Biology and Medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

E Fund CSI 300 Health Care ETF

Penghua SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

CStone Launches Nationwide Supply of Locally Made Pralsetinib as China Sales Surge

CStone Pharmaceuticals has successfully completed a share placement, raising over HK$1 billion by issuing 118 million shares at HK$8.97 each. This represents about 7.4% of the enlarged share capital and was priced at a 7.3% discount to the recent five-day average. The funds will enhance the company's capital base for ongoing operations and growth in the oncology sector. Previous placements in April and July 2025 raised approximately HK$232.29 million and HK$467.28 million, respectively. CStone focuses on developing innovative oncology therapies and is listed on the Hong Kong Stock Exchange.

CStone Pharmaceuticals Raises Over HK$1 Billion in Completed Share Placement

CStone Pharmaceuticals (HK:2616) announced it will present updated clinical data for its trispecific antibody CS2009 at the ASCO 2026 Annual Meeting. The data highlights progress from a global Phase I/II program in non-small cell lung cancer and advanced solid tumors, showing strong safety and encouraging efficacy. The company is preparing to launch Phase III multi-regional trials to enhance its position in immuno-oncology and expand its global registration strategy. CStone focuses on innovative oncology therapies and has a market cap of HK$14.39B.

CStone to Showcase Promising CS2009 Cancer Data Ahead of Global Phase III Push

CStone Pharmaceuticals (HK:2616) has unveiled three novel antibody-drug conjugate (ADC) candidates at the 2026 American Association for Cancer Research meeting. The lead candidate, CS5007, targets EGFR/HER3 and aims to overcome treatment resistance in oncology. Early data indicates CS5007 has superior plasma stability compared to existing ADCs, suggesting a favorable safety profile. CStone's ADC platform utilizes a hydrophilic linker and potent payload to enhance drug release and stability, reinforcing its position in the oncology market. The company focuses on innovative cancer therapies to improve patient outcomes.

CStone Showcases Three Novel ADC Candidates, Highlighting EGFR/HER3 Bispecific CS5007

06618

BABA

Trump stated that the Iran conflict is nearing its end, and the market expects a de-escalation of the conflict, with all three major U.S. stock indices rising, and the Hang Seng Index opening up 295 points. JD.com’s stock price rose by 6%, and technology stocks such as Alibaba and Tencent also saw increases. However, WuXi AppTec and CSTONE PHARMA saw their stock prices decline due to placement news. Lingrui's equity changed hands, resulting in a significant increase in its stock price

- President Trump stated that the conflict with Iran is "coming to an end," leading to heightened market expectations and a rise in U.S. stock indices, with the Dow up 317 points, the S&P gaining 81 points, and the Nasdaq increasing by 455 points.  
- International oil prices fell significantly, with New York oil dropping nearly 8% to $91.28, while gold prices rose over 2% to $4,840.73.  
- In Hong Kong, the Hang Seng index opened up 295 points, with tech stocks like Alibaba and Tencent showing gains, though some companies announced share placements resulting in declines.

Stheadline

JD.com

JD HEALTH

Alibaba

Tencent Holdings Limited

Tencent

JD-SW

TENCENT

JD LOGISTICS

KraneShares 2x Long JD Daily ETF

KraneShares 2x Long BABA Daily ETF

BABA 2x Long Daily ETF - GraniteShares

Trump claims the war is nearing its end, Hang Seng Index opens up 295 points, JD.com rises 6%, two pharmaceutical stocks surge, and another stock changes hands skyrockets 122% | Hong Kong stock market opens

CStone Pharmaceuticals (SEHK:2616) has received a Category I, A recommendation for Sugemalimab from the European Society for Medical Oncology, boosting investor interest. The stock is currently priced at HK$10.07, with a high P/S ratio of 47.9x, indicating overvaluation compared to industry peers. Despite a significant total return of over 300% in the past year, the company's negative earnings and high valuation raise concerns about future growth. Analysts suggest a potential fair value of HK$35.62 based on discounted cash flow, highlighting a significant discount in current trading.

Simplywall

First Trust NYSE Arca Biotech Index Fd

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng Health Care ETF(QDII)

Evaluating CStone Pharmaceuticals (SEHK:2616) After ESMO Category I A Backing For Sugemalimab

Goldman Sachs analyst maintained a Buy rating on CStone Pharmaceuticals yesterday and set a price target of HK$9.44. The company’s shares closed today at HK$8.75.End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Currently, the analyst consensus on CStone Pharmaceuticals is a Moderate Buy with an average price target of HK$9.87.

Goldman Sachs Sticks to Its Buy Rating for CStone Pharmaceuticals (2616)

CSTONE PHARMA-B(02616.HK)